×

Molecular diagnostic test for cancer

  • US 10,378,066 B2
  • Filed: 02/07/2017
  • Issued: 08/13/2019
  • Est. Priority Date: 09/15/2010
  • Status: Active Grant
First Claim
Patent Images

1. A method of predicting response of an individual to, and treating an individual with, a modulator of DNA-damage-related immune signalling, comprising:

  • a. measuring expression levels of at least five biomarkers in a test sample of cancer cells obtained from the individual, wherein the at least five biomarkers are selected from the group consisting of CXCL10, MX1, IDO1, IFI44L, CD2, GBP5, PRAME, ITGAL, LRP4, and APOL3;

    b. deriving a combined test score that captures the expression levels;

    c. providing a threshold score comprising information correlating the test score and responsiveness to the modulator of DNA-damage-related immune signalling;

    wherein the individual is predicted to respond to the modulator of DNA-damage-related immune signalling when the test score exceeds the threshold score; and

    d. treating the individual that is so predicted to respond with the modulator of DNA-damage-related immune signalling.

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×